Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval

Executive Summary

Genentech’s PD-L1 inhibitor Tecentriq could steal market share from the PD-1 inhibitors Opdivo and Keytruda in its new indication, but the Roche subsidiary’s drug is a year behind competitors from Bristol-Myers and Merck in NSCLC with seven Phase III trials under way to expand its reach in lung cancer.


Related Content

NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations
Cautious Roche Stresses: 'It's Not Only About APHINITY'
US Approvals Analysis: Stroke Device, IVDs Highlight October FDA Actions
PD-1 Deep Dive: Lung Cancer Market Braced For Change
Bristol Still Rules Immuno-Oncology, But For How Long?
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
Roche Raises IO Credentials On Tecentriq Lung Cancer Data
Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda
For Roche Immuno-Oncology, It’s Steady As She Goes
Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer


Related Companies